Genzymea Sanofi Company
Aldesleukin(Genzyme, a Sanofi Company)은 Gastric Cancer 표적 치료제로, B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5% (ClinicalTrials.gov NCT02858310). PK: t½ 2 h. 차별점: Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivit.
Gastric Cancer
B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recruiting
NK cell killing capacity and increases tumor growth inhibition when
linker creating a prodrug, TransCon IL-2 β/γ, with sustained release of IL
humanized antibody that binds to IL-2 at the same epitope as IL-2 Rα
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivit
checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity
immune-mediated diseases and cancer
biomarkers
resistance to current immune checkpoint inhibitors
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Genzymea Sanofi Company
Aldesleukin(Genzyme, a Sanofi Company)은 Gastric Cancer 표적 치료제로, B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5% (ClinicalTrials.gov NCT02858310). PK: t½ 2 h. 차별점: Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivit.
Gastric Cancer
B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recruiting
NK cell killing capacity and increases tumor growth inhibition when
linker creating a prodrug, TransCon IL-2 β/γ, with sustained release of IL
humanized antibody that binds to IL-2 at the same epitope as IL-2 Rα
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivit
checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity
immune-mediated diseases and cancer
biomarkers
resistance to current immune checkpoint inhibitors
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.